Open-house drug discount contracts for the vaginal ring active ingredient with gestagens and estrogens, ATC G02BB01

Summary

The tender concerns non-exclusive drug discount contracts for medicines whose active ingredient is the vaginal ring containing gestagens and estrogens (ATC G02BB01). The contract period runs from 01 November 2026 to 31 October 2028, using an open-house model that allows contracts to be concluded at any time. In the Open House procedure, medicines listed in the BfArM list under § 35 Abs. 5a SGB V (children's medicines) are excluded.